

Supplemental Online Content

Yang Z, Meng J, Mei X, et al. Brain radiotherapy with pyrotinib and capecitabine in patient with *ERBB2*-positive advanced breast cancer and brain metastases: a nonrandomized phase 2 trial. *JAMA Oncol*. Published online January 4, 2024. doi:10.1001/jamaoncol.2023.5791

eTable 1. Intracranial progression sites

eTable 2. Extracranial progression sites

eTable 3. Maintenance of neurocognitive function evaluated by MMSE

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Intracranial progression sites (n=21)

	No. of patients	
	FSRT (n=12)	WBRT (n=9)
Intracranial progression sites		
New lesions	7	6
Primary lesions	4 ^a	0
Both new and primary lesions	1 ^a	3

Abbreviations: FSRT, fractionated stereotactic radiotherapy; WBRT, whole-brain radiotherapy.

^aAmong the five patients with progression in the primary intracranial lesions who were treated with FSRT, four had a maximum tumor diameter greater than 3 cm.

eTable 2. Extracranial progression sites (n=8)

	No. of patients
Extracranial progression only	
Chest wall	1
Lung	1
Both intracranial and extracranial progression	
Lung ^a	2
Lung and pleura ^b	1
Lung and chest wall	1
Bone	1
Bone, soft tissue and skin	1

^aOne of two patients with intracranial progression and lung metastasis subsequently died due to aggravation of lung metastasis.

^bThe patient with intracranial progression and lung and pleura metastases subsequently died due to aggravation of extracranial metastases.

eTable 3. Maintenance of neurocognitive function evaluated by MMSE

	Total (n=40)	FSRT (n=29)	WBRT (n=11)	P
No. of patients who completed	28 (70)	22 (76)	6 (55)	--
MMSE at baseline				
MMSE score at baseline	27 (25.8-29)	28 (26-29)	26.5 (25.3-27)	--
≥ 27	17 (61)	14 (64)	3 (50)	--
Maintained neurocognitive function^a				
2 months after RT	20/22 (91)	17/17 (100)	3/5 (60)	.04
8 months after RT	19/20 (95)	15/15 (100)	4/5 (80)	.25
12 months after RT	13/14 (93)	11/11 (100)	2/3 (67)	.21
24 months after RT	6/6 (100)	4/4 (100)	2/2 (100)	> .99

Data are No. (%) or median (interquartile range), unless otherwise indicated.

Abbreviations: MMSE, Mini-Mental State Examination; RT, radiotherapy; FSRT, fractionated stereotactic radiotherapy; WBRT, whole-brain radiotherapy.

^aMaintained neurocognitive function was defined as reduction in MMSE score by no more than 2 points from baseline. The denominator was the number of surviving patients who completed MMSE at each time point. Fisher's exact test (2-sided) was used to compare the two radiotherapy subgroups.